Gut Instincts: Understanding the Role of Your Gut Microbiome in Mental Health
Gut health and mental health go hand in hand, according to recent research. These studies have suggested that the trillions of bacteria that live in our gut, collectively known as the gut microbiome, play an important role in regulating our mood, behavior, and cognitive function. Studies have shown that gut microbiome disturbances can contribute to anxiety- and trauma-related disorders, inflammation, and mood disorders (such as anxiety and depression) and that the gut-brain axis affects cognitive function.
Millions of people around the world suffer from anxiety disorders. There’s a strong link between the gut microbiome and anxiety, even though the exact causes aren’t completely understood. The gut-brain axis, which refers to the communication between the gut and the brain, plays a critical role in anxiety disorders. Here, we’ll explore the gut-brain axis in anxiety disorders and how diagnostic tests can help identify dysbiosis and inflammation in the gut.
The Gut Microbiome
The gut microbiome is the community of microorganisms that reside in the human gut. These microorganisms include bacteria, viruses, fungi, and protozoa. The gut microbiome plays an essential role in human health, including digestion, absorption of nutrients, and the regulation of the immune system.
Dysbiosis refers to an imbalance in the gut microbiota, where the number of harmful bacteria increases, and the beneficial bacteria decrease, which can cause inflammation in the gut. Inflammation occurs when the immune system is activated, and immune cells release chemicals that can damage tissues and organs.
Chronic inflammation can contribute to a variety of health problems, including inflammatory bowel disease, type 2 diabetes, and mental health issues. Recent research has suggested that the gut microbiome plays a crucial role in the development and management of anxiety disorders.
Anxiety disorders are characterized by excessive fear, worry, and anxiety; symptoms that can be debilitating and interfere with daily life. Research has shown that the gut microbiome can influence anxiety through several different mechanisms, including the production of neurotransmitters, the regulation of the immune system, and the communication between the gut and the brain via the vagus nerve.
One of the key ways that the gut microbiome affects anxiety is through the production of neurotransmitters. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The gut microbiome produces several neurotransmitters, including serotonin and GABA, which play a critical role in the regulation of mood and anxiety.
Certain gut bacteria influence neurotransmitters by producing short-chain fatty acids (SCFAs) through the fermentation of dietary fibers. These SCFAs can cross the blood-brain barrier and influence neurotransmitters such as increasing GABA, which has anxiolytic (anti-anxiety) effects, and decrease the production of glutamate, which has antigenic (anxiety-inducing) effects.
Neurotransmitter production is influenced by the gut microbiome through the production and conversion of tryptophan, an amino acid that is a precursor to serotonin and other catabolites. Alterations in the gut microbiome can lead to changes in the availability of tryptophan and thus affect serotonin production.
Alteration in the gut microbiome can lead to changes in the availability of neurotransmitters, such as dopamine and norepinephrine. These are involved in the regulation of mood and anxiety and alterations in the taxonomic composition of gut microorganisms contribute to the development of anxiety disorders.
Influence on the Immune System
The immune system, which plays a crucial role in the development and management of anxiety, is also influenced by the gut microbiome. The mechanisms through which the gut microbiome influences the immune system include affecting inflammation, impacting gut permeability, and the production of microbial metabolites.
The gut microbiome can affect inflammation by triggering an immune response. The immune response can be triggered by the gut microbiome producing pro-inflammatory cytokines and affecting the permeability of the intestinal wall.
A permeable intestinal wall allows harmful substances to enter the bloodstream and trigger an immune response. The immune response includes inflammation, and an overactive immune response can lead to chronic inflammation. Chronic inflammation has been linked to the development of anxiety disorders.
The gut microbiome plays a key role in regulating the inflammatory process through the production of metabolites. Metabolites such as SCFAs are produced by gut microbes during the fermentation of dietary fibers. SCFAs have been shown to have anti-inflammatory effects. Changes in the production of these metabolites can alter immune function and contribute to anxiety disorders.
Influence on the Vagus Nerve
The communication between the gut and the brain via the vagus nerve is another critical mechanism through which the gut microbiome can influence anxiety. The vagus nerve is the longest nerve in the body and connects the brain to major organs including the gut. It plays an important role in the communication between the gut and the brain, which is known as the gut-brain axis.
Recent research has shown that the gut microbiome can influence the function of the vagus nerve, which in turn can affect the regulation of anxiety. The molecules such as neurotransmitters, SCFAs, and other metabolites can interact with the vagus nerve and alter its function.
For example, butyrate has anti-inflammatory effects and it can stimulate the production of neuropeptides, such as oxytocin, which have been shown to have anxiolytic effects. Furthermore, the gut microbiome can directly activate the vagus nerve through the production of molecules such as lipopolysaccharides (LPS) and other microbial-associated molecular patterns (MAMPs). These molecules can trigger an immune response in the gut, which can lead to the activation of the vagus nerve and the release of neurotransmitters that can affect anxiety.
The Effect of Stress on the Microbiome
An interesting topic to consider in parallel to the influence of the gut microbiome on mood disorders is the influence of stress on the gut microbiome. Prolonged stress can disrupt the balance of the gut microbiome, which in turn leads to dysbiosis and inflammation as we have seen.
When the body is under stress, the hypothalamus in the brain releases corticotrophin-releasing hormone (CRH), which stimulates the pituitary gland to release adrenocorticotropic hormone (ACTH). This hormone, in turn, stimulates the adrenal glands to release cortisol, which is the primary stress hormone. Cortisol prepares the body for the fight-or-flight response by increasing blood sugar levels, heart rate, and blood pressure.
Several studies have shown that stress can alter the composition of the gut microbiome. For example, a study published in the journal Microbiome in 2017 found that mice subjected to social stress had a decrease in the diversity of their gut microbiota, with an increase in the abundance of harmful bacteria, such as Clostridium and Desulfovibrio.
Another study published in the journal Brain, Behavior, and Immunity in 2015 found that individuals who experienced early-life stress had lower levels of beneficial bacteria, such as Lactobacillus and Bifidobacterium, and higher levels of harmful bacteria, such as Clostridium.
Additionally, stress can cause changes in the gut-brain axis. The gut-brain axis is regulated by the enteric nervous system, which is often referred to as the “second brain.”
The enteric nervous system contains millions of neurons that communicate with the central nervous system through the vagus nerve. This communication pathway allows the gut to influence brain function, and vice versa.
Stress can disrupt the gut-brain axis by altering the activity of the enteric nervous system and the release of neurotransmitters, such as serotonin and GABA. Stress can also increase the permeability of the intestinal lining, allowing harmful bacteria and toxins to leak into the bloodstream, triggering an immune response and inflammation.
Stress can have a significant impact on the gut microbiome, leading to dysbiosis and inflammation. Dysbiosis and inflammation in the gut have been linked to a variety of health problems, including anxiety disorders.
Diagnostics to Identify Gut Dysbiosis and Inflammation
Diagnostic tests, such as stool tests and blood tests, can help to identify dysbiosis and inflammation in the gut, allowing for targeted treatment to improve gut health and mental health.
Overall, key factors in the development and management of anxiety disorders are influenced by the crucial roles the gut microbiome plays in regulating immune function, producing neurotransmitters, and influencing gut-brain communication via the vagus nerve. By understanding these mechanisms, we may be able to develop new therapies and treatments for individuals with anxiety disorders.
Currently, identifying dysbiosis and inflammation in the gut in people with anxiety disorders and attempting to return the gut to eubiosis are avenues researchers are exploring. Diagnostic tests such as fecal microbiota analysis can play a role in identifying dysbiosis and blood tests and stool tests can help identify inflammation in the gut.
Dysbiosis refers to an imbalance in the composition, diversity, or function of the microbiota, or a shift in the ratio of beneficial to harmful microorganisms that normally reside in a particular environment of the body, such as the gut. Eubiosis refers to a state of healthy, balanced microbial communities where the microorganisms within a particular community work in harmony to maintain a healthy and functional ecosystem.
Gut microbiome analysis can be done through a variety of common methods including culture-based methods, qPCR testing, 16S rRNA sequencing, shotgun metagenomic sequencing, quantitative microbiome profiling, and the analysis of gene expression, proteins, and metabolites.
There are a number of metrics that may provide valuable insight in the composition and balance of the microbial taxa of the gut including identifying specific species or strain, analyzing absolute and relative abundance, evenness, or richness of the different species or strains.
While these have not been standardized in a way that can be used as clinical diagnostics, they can provide valuable information about the composition of the gut microbiome, as well as any potential imbalances that may be contributing to anxiety disorders. Tests such as these can help clinicians develop targeted treatment plans for patients with anxiety disorders.
A Food Allergy Test, which can detect any food sensitivities or allergies that may be contributing to inflammation in the gut may also provide valuable diagnostic information. This test can help identify specific foods that may be causing inflammation and dysbiosis in the gut, which can in turn be treated with dietary changes or elimination diets.
Clinical Trials on the Gut-Brain Axis in Anxiety Disorders
Several clinical trials have been conducted to investigate the link between the gut microbiome and anxiety disorders through the use of interventions that modulate the gut microbiome to develop treatments for individuals with anxiety disorders.
One such example is the use of probiotics, which are live microorganisms that confer health benefits when consumed in adequate amounts. Probiotics can modulate the gut microbiome by promoting the growth of beneficial bacteria and reducing the abundance of harmful bacteria.
Several studies have investigated the use of probiotics for the treatment of anxiety disorders, with mixed results. For example, a randomized controlled trial published in 2017 found that a probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum reduced symptoms of anxiety and depression in individuals with major depressive disorder. Another study published in 2018 found that a probiotic supplement containing Lactobacillus casei reduced symptoms of anxiety and stress in medical students during an academic examination period.
A clinical trial investigating the effects of a prebiotic supplement on symptoms of social anxiety disorder (SAD) found that the prebiotic supplement significantly reduced symptoms of anxiety and improved the overall quality of life in patients with SAD, highlighting the potential for prebiotics in the treatment of anxiety disorders.
Another approach to modulating the gut microbiome is the use of fecal microbiota transplantation (FMT), which involves transferring fecal matter from a healthy donor into the gastrointestinal tract of a recipient. FMT is an effective treatment for recurrent Clostridium difficile infection, and there is emerging evidence to suggest that it may also be beneficial for individuals with mental health disorders.
A case report published in 2019 described a patient with obsessive-compulsive disorder who experienced significant improvements in symptoms following FMT. Another case series published in 2020 described three patients with bipolar disorder who received FMT and experienced improvements in mood and cognition.
It is important to note that these interventions are still in the early stages of the investigation, and further research is needed to determine their safety and efficacy for the treatment of anxiety disorders. However, the potential of modulating the gut microbiome to develop new treatments for mental health disorders is an exciting area of research that is generating increasing interest and attention.
The gut-brain axis plays a critical role in the development of anxiety disorders. Dysbiosis and inflammation in the gut can contribute to the onset and severity of anxiety symptoms and diagnostic tests can provide valuable information for the diagnosis and treatment of anxiety disorders.
Furthermore, recent research and clinical trials have shown that probiotics and prebiotics may be effective in reducing anxiety symptoms, suggesting that modulating the gut microbiome may be a promising avenue for the treatment of anxiety disorders.
As research in this area continues to expand, we will likely gain a greater understanding of the complex interplay between the gut microbiome and mental health. This knowledge could lead to more effective and personalized treatments for individuals with anxiety disorders, ultimately improving their quality of life.
Bruce-Keller AJ, Salbaum JM, Luo M, Blanchard E 4th, Taylor CM, Welsh DA, Berthoud HR. Obese-type Gut Microbiota Induce Neurobehavioral Changes in the Absence of Obesity. Biol Psychiatry. 2015 Oct 1;78(7):e1-e10. doi: 10.1016/j.biopsych.2015.03.020. Epub 2015 Mar 28. PMID: 25981167.
Damhorst GL, Adelman MW, Woodworth MH, Kraft CS. Current Capabilities of Gut Microbiome-Based Diagnostics and the Promise of Clinical Application. J Infect Dis. 2021 Jun 16;223(12 Suppl 2):S270-S275. doi: 10.1093/infdis/jiaa689. PMID: 33330938; PMCID: PMC8206793.
Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013 May;36(5):305-12. doi: 10.1016/j.tins.2013.01.005. Epub 2013 Feb 21. PMID: 23433939.
Kelly JR, Borre Y, O’Brien C, Patterson E, El Aidy S, Deane J, Kennedy PJ, Beers S, Scott K, Moloney G, Hoban AE, Scott L, Fitzgerald P, Ross P, Stanton C, Clarke G, Cryan JF, Dinan TG. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016 Nov;82:109-118. doi: 10.1016/j.jpsychires.2016.07.019. Epub 2016 Jul 20. PMID: 27538642.
Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011 Jul-Aug;2(4):256-61. doi: 10.4161/gmic.2.4.16108. Epub 2011 Jul 1. PMID: 21983070.
Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PW. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology (Berl). 2015 Aug;232(10):1793-801. doi: 10.1007/s00213-014-3810-0. Epub 2014 Nov 23. PMID: 25417199.
Thomas V, Clark J, Doré J. Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies. Future Microbiol. 2015;10(9):1485-504. doi: 10.2217/fmb.15.87. Epub 2015 Sep 8. PMID: 26347019.
Tillisch K, Labus JS. Advances in imaging the gut-brain axis: functional gastrointestinal disorders. Gastroenterology. 2011 Jun;140(7):407-11. doi: 10.1053/j.gastro.2011.01.057. Epub 2011 Feb 3. PMID: 21295183.
Zeng Q, Jun Wang, Guo Y, et al. Alterations in gut microbiota composition and metabolic parameters in 5α-reductase type 2 deficiency. J Transl Med. 2019;17(1):97. doi:10.1186/s12967-019-1845-5.
Introduction The field of diagnostic devices is complex, highly regulated, and fundamentally vital to public health. When designing, developing, and commercializing a new diagnostic product the stakes are high. Partnering with a CRO that holds an ISO...
Introduction The development and commercialization of diagnostic devices are a complex endeavor that involves a multitude of steps, from the initial conceptualization to market launch and post-market surveillance. Given the critical role diagnostic devices play in...
Dr. Bergein Overholt is widely recognized for his work as the developer of the flexible fiber sigmoidoscope-colonoscope in 1963, which is used in colonoscopy while serving in the Cancer Control Program of the U.S. Public Health Service. For his innovative work, he was...
Dr. Herbert Fritsche is Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. During his 40+ years at M.D. Anderson Cancer Center, Dr. Herbert Fritsche has focused his...
Eric Allyn will be a non-Director Board Observer and is the former Chairman of the Board of Directors of Welch Allyn, Inc, a company owned by the Allyn Family for 100 years. In September of 2015, as a result of tremendous consolidation in health care, Welch Allyn sold...
Tom Boyd will be a non-Director Board Observer and is the former Chairman of the Company. Tom Boyd was a member of the Company’s Board of Directors since it was incorporated in April 2005, and was the Company’s Chief Executive Officer from April 2005 to April 2014. He...
Paolo Rubatto is the founder of Start Capital, a London-based early-stage investment firm that invests globally. In addition, he is a co-founder and general partner at Beyond Ventures and an advisor at ScalingLab. Paolo has invested in and advised numerous technology...
Scott Gucciardi is a Senior Vice President of Solutions at Nextgen Healthcare (NASDAQ: NXGN). Scott Gucciardi is an executive and entrepreneur with over 25 years of experience in the global medical device and health information technology solutions markets. Scott...
Autumn Anfang is a highly experienced financial executive with over 25 years of leadership experience in various sectors including for-profit, non-profit, and higher education institutions. She currently serves as the Vice President of Business and Finance and Chief...
5678 Extra Rd. #123
San Francisco, CA 96120
Get in touch
Copyright © 2012-2020. All Rights Reserved.